Ixotatug vedotin

{
  "id": "MLC-T-ONC-014608",
  "term": "Ixotatug vedotin",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC) composed of ixotatug, a humanized monoclonal antibody directed against the tumor-associated antigen (TAA) claudin 6 (CLDN6; CLDN-6), linked to the auristatin derivative monomethyl auristatin E (MMAE) via a cleavable linker, with potential antineoplastic activity. Upon administration of ixotatug vedotin, the anti-CLDN6 antibody moiety targets and binds to CLDN6-expressing tumor cells. Upon binding, internalization, and linker cleavage, MMAE is released. MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. This induces cell death in CLDN6-expressing cancer cells. CLDN6, a transmembrane tight-junction protein and embryonic antigen, is overexpressed on a variety of tumor cells but is not expressed on normal, healthy adult cells.",
  "synonyms": [
    "ADC TORL-1-23"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/ixotatug-vedotin/"
}